Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sage Therapeutics

6.70
+0.10001.52%
Post-market: 6.900.1999+2.98%19:14 EDT
Volume:647.39K
Turnover:4.31M
Market Cap:419.56M
PE:-1.16
High:6.72
Open:6.52
Low:6.44
Close:6.60
Loading ...

Sage Therapeutics Price Target Cut to $12.00/Share From $14.00 by HC Wainwright & Co.

Dow Jones
·
12 Feb

SAGE Therapeutics (SAGE) Gets a Buy from Scotiabank

TIPRANKS
·
12 Feb

SAGE Therapeutics (SAGE) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
12 Feb

SAGE Therapeutics: Hold Rating Amid Uncertainty and Strategic Exploration

TIPRANKS
·
12 Feb

Hold Rating on SAGE Therapeutics Amid Underwhelming Sales and Strategic Uncertainties

TIPRANKS
·
12 Feb

Sage Therapeutics Inc : Scotiabank Cuts Target Price to $12 From $14

THOMSON REUTERS
·
12 Feb

Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ...

GuruFocus.com
·
12 Feb

Sage Therapeutics Reports Strong 2024 Performance

TIPRANKS
·
12 Feb

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW) and SAGE Therapeutics (SAGE)

TIPRANKS
·
12 Feb

SAGE Therapeutics: Hold Rating Amid Financial Challenges and Uncertain Outlook

TIPRANKS
·
12 Feb

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
12 Feb

SAGE Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Feb

Sage Therapeutics says existing cash to support operations through mid-2027

TIPRANKS
·
12 Feb

Sage Therapeutics Q4 2024 GAAP EPS $(1.56) Misses $(1.43) Estimate, Sales $12.815M Miss $14.441M Estimate

Benzinga
·
12 Feb

Sage Therapeutics Inc: Cash Runway Expected to Support Operations to Mid-2027

THOMSON REUTERS
·
12 Feb

BRIEF-SAGE Therapeutics Q4 Product Revenue USD 442 Thousand

Reuters
·
12 Feb

Sage Therapeutics Q4 Product Revenue USD 442 Thousand

THOMSON REUTERS
·
12 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
10 Feb

SAGE Therapeutics Inc expected to post a loss of $1.51 a share - Earnings Preview

Reuters
·
08 Feb

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

Zacks
·
04 Feb